FIGURE 3.

CCL5-mediated glucose uptake is mTOR-dependent. A, activated PB T cells were either left untreated, treated with 20 ng/ml IL-2, or the indicated doses of CCL5 for 2 h. In parallel, cells were pretreated with 10 mm of 2-DG for 1 h prior to treatment with 10 nm CCL5. At time 0, 2 μCi/rxn of 2-deoxy-d-[³H] glucose was added to the cultures. Reactions were quenched and radioactivity measured with a liquid scintillation counter. Data are representative of three independent studies. B, cells were pretreated with either dimethyl sulfoxide (DMSO; carrier) or 50 nm of rapamycin for 1 h prior to treatment with 10 nm CCL5. Tritiated glucose uptake was measured as in A. Data are representative of two independent studies. C, cells were pretreated with CCR5 antagonist, TAK-779 for 1 h prior to treatment with 10 nm CCL5. Tritiated glucose uptake was measured as in A.